CVE-2026-123052: CIPCarbone Farmasimplex CeliachiaRL · Use of Hard-coded Credentials
Affects CIPCarbone Farmasimplex CeliachiaRLSource CVE Database V5
Not known to be exploited · CVSS 4.7 Medium : upgrade to 16.2.0 when convenient.
Data as of 17 Nov 2026, 14:54 UTC
Thin evidence
One scorer or none| CNA (ENISA) | CVSS 4.0 | 4.7 |
|---|
- Patch
- Available – fixed in 16.2.0
CVSS:4.0/AV:L/AC:L/AT:N/PR:N/UI:N/VC:H/VI:L/VA:N/SC:N/SI:N/SA:N/E:UExploitation evidence
Disclosed: evidence found.
CVE published 17 Nov 2026
Detectable: no evidence on record.
No public nuclei template indexed
Weaponized: no evidence on record.
No public exploit code indexed in Metasploit or Exploit-DB
Exploited in the wildExploited: no evidence on record.
Not in CISA KEV and no source reports exploitation
Observed by OffSeq MirageSeen by Mirage: no evidence on record.
No attack traffic recorded by OffSeq Mirage sensors
A missing step is not evidence of safety. Sources: cve.org (opens in a new tab), the Metasploit, Exploit-DB and nuclei-templates index as of 16 Nov 2026.
What to do
Upgrade CIPCarbone Farmasimplex CeliachiaRL to 16.2.0.
Affected software
| Product | Affected | Fixed in |
|---|---|---|
| CIPCarboneFarmasimplex CeliachiaRL | Affected
| Fixed in
|
AI-suggested
Upgrade Farmasimplex CeliachiaRL to version 16.2.0 or later, where the use of shared OAuth credentials has been addressed. This official fix eliminates the vulnerability by removing or properly segregating credentials. No additional mitigation is required once the patch is applied.
Description
CIPCarbone Farmasimplex CeliachiaRL integration component uses shared OAuth credentials across multiple customer installations. This hard-coded credential reuse allows an attacker who obtains credentials from one installation to potentially access or modify data in others. The vulnerability affects versions prior to 16.2.0 and has been fixed in version 16.2.0. The CVSS score is 4.7, indicating a medium severity risk.